Why NASDAQ:CPRX qualifies as a high growth stock.

In this article we will dive into CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) as a possible candidate for growth investing. Investors should always do their own research, but we noticed CATALYST PHARMACEUTICALS INC showing up in our Louis Navellier growth screen, which makes it worth to investigate a bit more.

A Deep Dive into CATALYST PHARMACEUTICALS INC's Growth Metrics.

• CATALYST PHARMACEUTICALS INC has a healthy Return on Equity(ROE) of 21.61%. This demonstrates the company's efficient utilization of capital and indicates its commitment to driving profitability.
• CATALYST PHARMACEUTICALS INC has consistently surpassed EPS estimates in the last 4 quarters, reflecting its strong financial performance and effective management. This trend suggests the company's ability to generate positive earnings surprises and drive shareholder value.
• CATALYST PHARMACEUTICALS INC has demonstrated strong 1-year revenue growth of 32.13%, reflecting revenue momentum and its ability to generate consistent top-line expansion. This growth underscores the company's strong market position and its potential for future success.
• The q2q revenue growth of 25.33% of CATALYST PHARMACEUTICALS INC highlights the company's ability to generate incremental revenue and suggests positive market demand for its products or services.
• CATALYST PHARMACEUTICALS INC has experienced notable growth in its operating margin over the past year, reflecting improved operational performance. This growth suggests the company's ability to generate higher profits from its core business activities.
• With a favorable trend in its free cash flow (FCF) over the past year, CATALYST PHARMACEUTICALS INC demonstrates its ability to generate robust cash flows and maintain financial stability. This growth reflects the company's focus on efficient capital allocation and cash management.
• CATALYST PHARMACEUTICALS INC has demonstrated consistent growth in its earnings per share (EPS) from one quarter to another (Q2Q), with a 221.0% increase. This indicates improving financial performance and the company's effective management of its operations.
• Over the past 3 months, analysts have adjusted their EPS Estimate for CATALYST PHARMACEUTICALS INC with a 29.77% change. This highlights the evolving outlook on the company's EPS potential.
• The recent financial report of CATALYST PHARMACEUTICALS INC demonstrates a 221.0% increase in quarterly earnings compared to the previous quarter. This growth indicates positive momentum in the company's financials and suggests a promising upward trend
• The earnings per share (EPS) growth of CATALYST PHARMACEUTICALS INC are accelerating: the current Q2Q growth of 221.0% is above the previous year Q2Q growth of -245.0%. Earnings momentum and acceleration are key for high growth systems.

Fundamental analysis of NASDAQ:CPRX

Every day ChartMill assigns a Fundamental Rating to every stock. The score ranges from 0 to 10 and is determined by evaluating multiple fundamental indicators and properties.

Taking everything into account, CPRX scores 8 out of 10 in our fundamental rating. CPRX was compared to 572 industry peers in the Biotechnology industry. CPRX scores excellent points on both the profitability and health parts. This is a solid base for a good stock. CPRX is evaluated to be cheap and growing strongly. This does not happen too often! These ratings would make CPRX suitable for value and growth and quality investing!

Check the latest full fundamental report of CPRX for a complete fundamental analysis.

Our Lois Navellier screen will find you more ideas suited for growth investing.

Disclaimer

This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.